Share Price and Basic Stock Data
Last Updated: November 3, 2025, 9:21 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Mangalam Drugs and Organics Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹64.5 and a market capitalization of ₹102 Cr. The company reported a total revenue of ₹372 Cr for the financial year ending March 2023, reflecting a decline compared to ₹451 Cr in the previous year. Quarterly sales figures indicate fluctuating performance, with the highest quarterly sales at ₹109 Cr in June 2022 and the lowest at ₹63 Cr in December 2022. The latest quarterly results show sales of ₹82 Cr in September 2023, suggesting a downward trend in revenue generation. The trailing twelve-month sales stood at ₹299 Cr, indicating ongoing challenges in maintaining consistent revenue growth. Overall, the revenue trajectory indicates volatility, which could be attributed to market conditions or operational issues within the company.
Profitability and Efficiency Metrics
The profitability of Mangalam Drugs and Organics Ltd has shown significant volatility, with a reported operating profit margin (OPM) of -8% and a net profit margin of -2.11% for the financial year ending March 2025. The operating profit stood at ₹26 Cr in March 2023, a decline from ₹49 Cr in March 2022. The company recorded a negative net profit of ₹9 Cr for FY 2024, although it rebounded to a net profit of ₹7 Cr in FY 2025. The interest coverage ratio (ICR) improved to 2.43x for FY 2025, indicating a better ability to service debt, despite previous losses. Efficiency metrics such as return on equity (ROE) at 4.71% and return on capital employed (ROCE) at 8.03% reflect a need for improved operational efficiency, especially when compared to industry norms. The company’s cash conversion cycle (CCC) of 148 days highlights inefficiencies in managing working capital.
Balance Sheet Strength and Financial Ratios
Mangalam Drugs and Organics Ltd reported total reserves of ₹133 Cr against borrowings of ₹96 Cr, providing a reserve-to-borrowing ratio that indicates moderate financial stability. The current ratio stood at 1.04, suggesting that the company is capable of meeting its short-term liabilities. However, the total debt-to-equity ratio of 0.54x indicates a relatively leveraged position, which could pose risks in adverse market conditions. The price-to-book value (P/BV) ratio is currently at 0.78x, suggesting that the stock is undervalued relative to its book value, which stood at ₹94.12 per share for March 2025. The enterprise value (EV) of ₹196.06 Cr is consistent with its operational revenue, reflecting a reasonable valuation. Nonetheless, the company faces challenges in improving its profitability metrics, which could impact investor confidence and the overall financial health of the firm.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mangalam Drugs and Organics Ltd reveals a stable promoter holding of 50.30%, indicating strong insider confidence in the company’s direction. Foreign institutional investors (FIIs) have increased their stake to 0.53%, up from 0.10% in previous quarters, suggesting a growing interest from foreign investors. The public shareholding stands at 49.16%, while the number of shareholders has increased to 19,728 as of June 2025, indicating a broad base of retail investors. However, the absence of domestic institutional investment (DIIs) raises questions about institutional confidence in the stock’s prospects. The gradual increase in FIIs could be a positive signal, but the overall lack of institutional backing may limit upward momentum in stock performance. Overall, while the stable promoter holding may instill confidence, the low institutional interest could pose a risk to share price stability.
Outlook, Risks, and Final Insight
The outlook for Mangalam Drugs and Organics Ltd hinges on its ability to stabilize revenue and improve profitability. Key strengths include a solid reserve base and a manageable debt level, which provide some cushion against operational challenges. Conversely, risks include fluctuating sales performance and ongoing profitability issues that could deter new investments. The company’s ability to manage its cash conversion cycle effectively will be crucial to enhancing operational efficiency. Furthermore, the lack of significant institutional investment could limit stock performance in volatile market conditions. Should the company successfully implement strategic initiatives to enhance its operational efficiency and profitability, it could improve investor sentiment and drive stock performance. However, failure to address these challenges may lead to further declines in market confidence and financial stability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Mangalam Drugs and Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 33.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,079 Cr. | 464 | 479/192 | 114 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.1 Cr. | 24.0 | 29.1/17.0 | 36.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,966.35 Cr | 1,197.73 | 54.46 | 195.30 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 109 | 108 | 63 | 91 | 87 | 82 | 97 | 102 | 77 | 80 | 89 | 73 | 57 |
| Expenses | 99 | 100 | 57 | 91 | 91 | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 |
| Operating Profit | 10 | 8 | 6 | 0 | -3 | 2 | 7 | 12 | 8 | 9 | 9 | 10 | -5 |
| OPM % | 9% | 8% | 10% | 0% | -4% | 3% | 7% | 11% | 11% | 11% | 10% | 14% | -8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 |
| Profit before tax | 4 | 3 | 1 | -6 | -10 | -5 | 0 | 4 | 1 | 1 | 1 | 2 | -13 |
| Tax % | 29% | 29% | 16% | -22% | -7% | -25% | -920% | 10% | -356% | -125% | 5% | 91% | 6% |
| Net Profit | 3 | 2 | 0 | -4 | -10 | -4 | 0 | 4 | 3 | 3 | 1 | 0 | -14 |
| EPS in Rs | 1.90 | 1.41 | 0.27 | -2.77 | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 |
Last Updated: August 20, 2025, 7:15 am
Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 16.00 Cr..
- For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 1.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -5.00 Cr., marking a decrease of 15.00 Cr..
- For OPM %, as of Jun 2025, the value is -8.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to -8.00%, marking a decrease of 22.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to -13.00 Cr., marking a decrease of 15.00 Cr..
- For Tax %, as of Jun 2025, the value is 6.00%. The value appears to be improving (decreasing) as expected. It has decreased from 91.00% (Mar 2025) to 6.00%, marking a decrease of 85.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -8.67. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to -8.67, marking a decrease of 8.76.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:53 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 299 |
| Expenses | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 276 |
| Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | 23 |
| OPM % | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 5% | 11% | 8% |
| Other Income | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 15 |
| Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
| Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -9 |
| Tax % | -22% | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% | |
| Net Profit | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -9 |
| EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 | -6.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 300.00% | 166.67% | 37.50% | -9.09% | -140.00% | 200.00% | 250.00% | -28.57% | -95.00% | -1000.00% | 177.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -129.17% | -46.59% | -130.91% | 340.00% | 50.00% | -278.57% | -66.43% | -905.00% | 1177.78% |
Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: October 10, 2025, 2:30 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 |
| Borrowings | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 |
| Other Liabilities | 25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 |
| Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
| Fixed Assets | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 |
| CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 |
| Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 |
| Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
- For Reserves, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 127.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 6.00 Cr..
- For Borrowings, as of Mar 2025, the value is 96.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 107.00 Cr. (Mar 2024) to 96.00 Cr., marking a decrease of 11.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 114.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Mar 2024) to 114.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 147.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 5.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 201.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Mar 2024) to 201.00 Cr., marking a decrease of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 359.00 Cr.. The value appears strong and on an upward trend. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (133.00 Cr.) exceed the Borrowings (96.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -67.00 | -58.00 | -22.00 | -19.00 | -22.00 | -55.00 | -28.00 | -17.00 | -39.00 | -63.00 | -90.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
| Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
| Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
| Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
| Working Capital Days | 29 | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 |
| ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.25 | -5.73 |
| Diluted EPS (Rs.) | 4.25 | -5.73 |
| Cash EPS (Rs.) | 14.74 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Revenue From Operations / Share (Rs.) | 201.05 | 232.87 |
| PBDIT / Share (Rs.) | 22.95 | 11.05 |
| PBIT / Share (Rs.) | 12.46 | 1.80 |
| PBT / Share (Rs.) | 3.02 | -7.00 |
| Net Profit / Share (Rs.) | 4.25 | -5.73 |
| NP After MI And SOA / Share (Rs.) | 4.25 | -5.73 |
| PBDIT Margin (%) | 11.41 | 4.74 |
| PBIT Margin (%) | 6.19 | 0.77 |
| PBT Margin (%) | 1.50 | -3.00 |
| Net Profit Margin (%) | 2.11 | -2.46 |
| NP After MI And SOA Margin (%) | 2.11 | -2.46 |
| Return on Networth / Equity (%) | 4.51 | -6.68 |
| Return on Capital Employeed (%) | 11.27 | 1.67 |
| Return On Assets (%) | 1.83 | -2.71 |
| Long Term Debt / Equity (X) | 0.06 | 0.09 |
| Total Debt / Equity (X) | 0.54 | 0.64 |
| Asset Turnover Ratio (%) | 0.90 | 0.00 |
| Current Ratio (X) | 1.04 | 1.07 |
| Quick Ratio (X) | 0.31 | 0.31 |
| Inventory Turnover Ratio (X) | 1.30 | 0.00 |
| Interest Coverage Ratio (X) | 2.43 | 1.26 |
| Interest Coverage Ratio (Post Tax) (X) | 1.45 | 0.34 |
| Enterprise Value (Cr.) | 196.06 | 233.41 |
| EV / Net Operating Revenue (X) | 0.61 | 0.63 |
| EV / EBITDA (X) | 5.40 | 13.34 |
| MarketCap / Net Operating Revenue (X) | 0.36 | 0.39 |
| Price / BV (X) | 0.78 | 1.08 |
| Price / Net Operating Revenue (X) | 0.36 | 0.39 |
| EarningsYield | 0.05 | -0.06 |
After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.74. This value is within the healthy range. It has increased from 3.52 (Mar 24) to 14.74, marking an increase of 11.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 201.05. It has decreased from 232.87 (Mar 24) to 201.05, marking a decrease of 31.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 22.95. This value is within the healthy range. It has increased from 11.05 (Mar 24) to 22.95, marking an increase of 11.90.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.46. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 12.46, marking an increase of 10.66.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has increased from -7.00 (Mar 24) to 3.02, marking an increase of 10.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 4.74 (Mar 24) to 11.41, marking an increase of 6.67.
- For PBIT Margin (%), as of Mar 25, the value is 6.19. This value is below the healthy minimum of 10. It has increased from 0.77 (Mar 24) to 6.19, marking an increase of 5.42.
- For PBT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has increased from -3.00 (Mar 24) to 1.50, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 5. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 8. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.51. This value is below the healthy minimum of 15. It has increased from -6.68 (Mar 24) to 4.51, marking an increase of 11.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from 1.67 (Mar 24) to 11.27, marking an increase of 9.60.
- For Return On Assets (%), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 1.83, marking an increase of 4.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 0.64 (Mar 24) to 0.54, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.90. It has increased from 0.00 (Mar 24) to 0.90, marking an increase of 0.90.
- For Current Ratio (X), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.04, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.31.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.30, marking an increase of 1.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 2.43, marking an increase of 1.17.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 3. It has increased from 0.34 (Mar 24) to 1.45, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 196.06. It has decreased from 233.41 (Mar 24) to 196.06, marking a decrease of 37.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.61, marking a decrease of 0.02.
- For EV / EBITDA (X), as of Mar 25, the value is 5.40. This value is within the healthy range. It has decreased from 13.34 (Mar 24) to 5.40, marking a decrease of 7.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For Price / BV (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.08 (Mar 24) to 0.78, marking a decrease of 0.30.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to 0.05, marking an increase of 0.11.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mangalam Drugs and Organics Ltd:
- Net Profit Margin: 2.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.27% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.51% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.45
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Rupam Building, 3rd Floor, 239, P.D. Mello Road, Mumbai Maharashtra 400001 | contactus@mangalamdrugs.com http://www.mangalamdrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Govardhan Murlidhar Dhoot | Chairman & Managing Director |
| Mr. Brijmohan Murlidhar Dhoot | Whole Time Director |
| Mr. Rakesh Kishinchand Milwani | Non Exe.Non Ind.Director |
| Mr. Rukmesh Prabhukumar Dhandhania | Independent Director |
| Mrs. Nidhi Shantanu Mundada | Independent Director |
| Mr. Praveen Saxena | Independent Director |
FAQ
What is the intrinsic value of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd's intrinsic value (as of 03 November 2025) is 54.13 which is 19.21% lower the current market price of 67.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 105 Cr. market cap, FY2025-2026 high/low of 130/62.8, reserves of ₹133 Cr, and liabilities of 359 Cr.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
The Market Cap of Mangalam Drugs and Organics Ltd is 105 Cr..
What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 03 November 2025?
The current stock price of Mangalam Drugs and Organics Ltd as on 03 November 2025 is 67.0.
What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mangalam Drugs and Organics Ltd stocks is 130/62.8.
What is the Stock P/E of Mangalam Drugs and Organics Ltd?
The Stock P/E of Mangalam Drugs and Organics Ltd is .
What is the Book Value of Mangalam Drugs and Organics Ltd?
The Book Value of Mangalam Drugs and Organics Ltd is 93.9.
What is the Dividend Yield of Mangalam Drugs and Organics Ltd?
The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.
What is the ROCE of Mangalam Drugs and Organics Ltd?
The ROCE of Mangalam Drugs and Organics Ltd is 8.03 %.
What is the ROE of Mangalam Drugs and Organics Ltd?
The ROE of Mangalam Drugs and Organics Ltd is 4.71 %.
What is the Face Value of Mangalam Drugs and Organics Ltd?
The Face Value of Mangalam Drugs and Organics Ltd is 10.0.